Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7521159 | 0.89 | SIGMAR1 (0.66) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL17973027 | 0.83 | ALOX15 (0.45) | SIGMAR1HTR1A | |
| SCHEMBL24968330 | 0.82 | PPARG (0.44) | SIGMAR1HTR1A | |
| SCHEMBL1307809 | 0.80 | POLB (0.53) | KDM4EDRD2HTR1A | |
| SCHEMBL7855443 | 0.80 | SIGMAR1 (0.63) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL30350966 | 0.79 | SIGMAR1 (0.66) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9766008 | 0.78 | SIGMAR1 (0.60) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL9766043 | 0.78 | SIGMAR1 (0.82) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL8275473 | 0.76 | SIGMAR1 (0.50) | SIGMAR1KDM4ECYP1A2GAACYP2C9 | |
| SCHEMBL2615375 | 0.74 | HTR1A (0.61) | SIGMAR1KDM4ECYP1A2GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613901-B2 | For therapy and prophylaxis of neuropsychochological disorders such as schizophrenia and other central nervous system diseases | NEUROGEN CORPORATION | 2003-09-02 | — | — | US | disclosed |
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | NEUROGEN CORPORATION | 2002-10-03 | — | — | US | disclosed |
| US-6441175-B1 | 1-(N'-arylalkylaminoalkyl)aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-08-27 | — | — | US | disclosed |
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| US-6313141-B1 | FOR THERAPY OF SCHIZOPHRENIA, PSYCHOTIC DEPRESSION, MANIA, PARKINSON'S DISEASE AND TARDIVE DISKINESIA | NEUROGEN CORPORATION | 2001-11-06 | — | — | US | disclosed |
| US-6252077-B1 | PSYCHOLOGICAL, NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-06-26 | — | — | US | disclosed |
| EP-0991642-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 2000-04-12 | — | — | EP | disclosed |
| US-6031097-A | 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands | NEUROGEN CORPORATION (US) | 2000-02-29 | — | — | US | disclosed |
| US-5972945-A | FOR TREATING PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES | NEUROGEN CORPORATION (US) | 1999-10-26 | — | — | US | disclosed |
| WO-1999021848-A2 | NOVEL 1-(N'-(ARYLALKYLAMINOALKYL))AMINOISOINDOLES; A NEW CLASS OF DOPAMINE RECEPTOR SUBTYPE SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998056786-A1 | 2-AMINOALKYLAMINOQUINOLINES AS DOPAMINE D4 LIGANDS | NEUROGEN CORPORATION (US) | 1998-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143019-A1 | 2-aminoalkylaminoquinolines as dopamine D4 ligands | SLC6A3, DRD4, ADRA2C | SIGMAR1 56/4885KDM4E 1311/4885CYP1A2 697/4885 |
| US-20020052496-A1 | Novel 1-(N'-(arylalkylaminoalkyl)) aminoisoquinolines: a new class of dopamine receptor subtype | DRD2, DRD1, CHRNA5 | SIGMAR1 102/4885KDM4E 3234/4885CYP1A2 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.